Scholars Central

Short communicationPublished 17 Aug 2021

Brief Overview on "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture"

Authors: Warren K. Weston, Jane A. Harness, Aarthi Narayanan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The COVID-19 pandemic remains a pressing global challenge. Worldwide mortality attributable to COVID-19 now exceeds 4 million deaths. There is an urgent need for developing novel therapeutics to treat SARS-CoV-2. Our recent study showed brilacidin, a synthetic small molecule with peptide-like properties, potently inhibits SARS-CoV-2 in cell culture. Additionally, brilacidin exhibited in vitro inhibition in combination with remdesivir, the only FDA-approved drug for treatment of COVID-19. Brilacidin is currently undergoing Phase 2 clinical testing for treatment of moderate-to-severe COVID-19 in hospitalized patients.

Subjects

Microbiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Archives of Clinical Microbiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalArchives of Clinical Microbiology
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Warren K. Weston”
  • BylineArticles whose byline prints “Jane A. Harness”
  • BylineArticles whose byline prints “Aarthi Narayanan”